Episode Details
Back to Episodes
Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs
Published 5 months ago
Description
He describes physician, patient, and payor feedback from this closely watched launch. Plus, praliciguat, and why Akebia bought a targeted complement inhibitor from Q32 Bio.